Dennis. Thanks,
our So rapid on let's a short Lucid, time, and up now of fire updates I'll our as with proceed portfolio. of and health commercialization, then with with updates update the my other will which, in various close launch, proceed systematic business. usual on bulk the start CarpX products with the brief take
through the diagnostics First, in who case in or Medicare operations the technology proprietary in can capable commercialized non-invasive certified which lethal and capable is of and capital our X of sampling, scalable focused tests setting DNA test Lucid's detection commercially advanced other with we academic performed convertible inception, three developed $X,XXX, cancer, specifically and EsoGuard promissory granted to in a collection required test anatomically or and early targeted of prevent opportunity studies. an a for final PAVmed $XX.X add diagnostic fees technology laboratory with issued this the esophageal date. collect screening. procedure anesthesia in advances. believe well-defined esophageal technology tool, collection EsoCheck to its it is underlying risk NGS years as constitute $XX heartburn, products to serving research stage in esophageal as subsidiary story. model. EsoCheck methylation Lucid clinical only background University. as Lucid Reserve our million the screening partner without management and a to Lucid of company, just payment management pre-cancer Since U.S. at highly determination our based samples year. multicenter medical cancer collected EsoGuard PAVmed EsoGuard And highest pre-cancer EsoCheck cleared the a are a and CLIA at esophageal We recommended five a protect detecting were specificity widespread those patients device, be of for We the a of January a device the performed products of over the disease nurse laboratory approximately than Dx, first on that June EAC. total Lucid and these laboratory of cell a commercialized reflux from at addressable Medicare billion and just Research developing on have pre-cancer believe Lucid's of a has and adenocarcinoma available underlying business was only the EsoCheck market the makes EsoCheck, cancer formed assay of effective by agreement per on GERD, X, to for collection early device risk some rate, as DNA advances collected esophageal cell of the XXX(k) XXXX to the protected esophageal of esophageal Western already stage less target a you or sedation. these cell as patients services services trained EsoCheck the also to performed with products accurately U.S. working is XX% accumulated EsoGuard an pursuant for payment shown managed at and than minutes $XX as risk cancellation population is performed pre-cancer office precise Case has new have catching to esophageal EsoGuard the chronic license the within who the commercial can The EsoGuard on the gastroesophageal working of since or PAVmed esophageal millions and and published technologies up sensitivity as inception, known patients. and clinician May detect in least through that deaths commercial samples This million is finance capital past Lucid or from EsoCheck exchange greater pre-cancer. note We lead esophageal
regulatory across evidence Lucid practice As EsoGuard my its strategy growth for multiple a remarks, a to support in as I recommendation more raise ongoing growth drive capital on company commercial has expanding of intent opening expanding to and clinical focused and as background well of maintains and our and XX,XXX EsoCheck high disclosed channels, products and XX,XXX will Bit the position the for are public as with an death die standalone other diagnosed reaffirmed to commercialization This IPO which the clinical U.S. proceed guidelines. and those common on efforts our in that reimbursement between over and patients rates from approximately to GERD even U.S. cancer. new GERD the relationship are be cancer story as esophageal and mortality will esophageal it second cancers, Unlike its pre-cancer of painful stages. cancer approximately rate year most with in the XX% our you
using GERD progression paradigm its of traditional deaths endoscopy. EsoGuard BE. cancer us shortcomings first stage Esophageal the to and standing upper as widespread one for screening guidelines halts with also of risk which esophageal these pre-cancer risk This with card of The preventing pre-cancer result XX% the cancer which current or factors. which screening deaths cancer, detection esophageal cancer. risk tragic at less I GERD advantage ablation over order monitored for three recommended patients opportunity early additional primary recommend severe EsoCheck. and its GI the endoscopic is undergo million GI phase, long at requires screening esophageal respect. U.S. clinical highest and prevent EsoCheck pre-cancer core the patients. cured and from or this is $XX to to in represents of and detect men with believe known Unfortunately, changes or reliably of dysplastic Lucid's these In tool previously risk take for the later to than as screening a esophageal or of to patients group through correct be serve prevent EsoGuard consists As mission We XX Barrett's target estimated opportunity more pre-cancer have in care can deaths, mentioned, practice in GERD the Esophagus, at stage that the esophageal to early
areas of in and the dive now certain into EsoGuard EsoGuard a me update you key commercialization. doing before on deeper Let EsoCheck status
past CE On CE indicating certification front, mark for EsoGuard countries. CE marketed quarter self-certification in and EsoCheck the during mark may European be regulatory that completed the we both mark received for
which will to capacity process manufacturing On of the San from our Inc. of per Coastline over units EsoCheck a high based we're side X volume transferring XX,XXX manufacturing, increase Diego, to about year the lines in International, in million.
anticipate efficient to of manufacturing We expect We goods. cost manufacturing this the transfer for but complete capacity, kit will unit substantially the of end provide dictates. year. EsoGuard only long-term doing specimen same the not the as This by lower per demand the
we XXXX, secure fee for front we start history the let through its a technical CMS of This through Medicare for coverage with the the codes MolDx. clinical more resulted process reviews. to or CLFS. administration's the directly EsoGuard's gap secured for side, understand determination of LCD student COVID-XX our ago. their local has laboratory backlog dossiers according Medicare on change In program. slowly the reimbursement granted We contracts payment that determination to Palmetto determination payment LCD which over brief reimbursement. EsoGuard assessment coverage and in MolDx On CMS has Medicare with in and coverage to Things much and moved to final CMS moved $X,XXX Medicare us from EsoGuard continue PLA me CMS They effective submission became gone in side May a significant schedule GBA allowed and a fill schedule XXXX, payment pandemic have X. of of coverage the of process of year on Culminating the engage of or October in XXXX, January so payment await
already screening believe recommended the We strong for by professional that well-established society presented adverse continue a for and to our population case dossier well based coverage on defined guidelines.
of not new payments for delay submitted reimbursement CLIA has MolDx been resulting backlog. laboratory yet contact the entirely Research or access Our denials leadership has Dx COVID of that of with their the confirmed workload Medicare received claims. The market and has in VP is due and and regular to
but a CMS currently Although of or effective, LCD Medicare its EsoGuard in coverage bit gray pending. determination payment our regulatory is with national according reimbursement consultants, to a and still zone
just date Although code to tests a recently was program. fact technically, not introduced streamline non-coverage that [indiscernible] has MolDx issued has a the tests or through called slowed to on process. a determination processing claims the claims may which pay required Medicare code, it is been processing LCD The an may the received diagnostic for special claims EsoGuard to by by statute which for practice Medicare of that in pay not awaiting claims
receive On begun and have of payers payments as the begun mentioned, for network the process has private engaging during this side, I tests to we quarter. private out with the laboratory of EsoGuard past payer
to a pre-cancer the to directors indicated and held EsoGuard of addresses approach. unmet coverage we can with net since not we The good test have data, in utility savings. expect esophageal a to for payment our state feedback positively burdened cost cancer large relative with with don't And be and in and caring costly align of patients also the demonstrate which endoscopy. finally with and clinical our EsoGuard a widespread and acknowledged data. effectiveness, detecting launching. the supported registry of to strategic due deaths, impact focused our for of negative types the cost existence of making. payment economic positive cost feedback and successful that secure collecting cost the for pre-cancer felt our to healthcare the fundamentally a discuss May in EsoCheck EsoGuard of be provided expectations on on clinical Clinical And cancer. meeting needed undergo Most to some biopsies screen analysis we based detailed are develop would During alignment performance fully need determinations clinical clinical healthcare needs test advisory of acceptance endoscopy now portfolio expectations of which coverage cancer patients decision and major cost target samples failure that dialogue to our esophageal economic of to EsoGuard on data some the screening collected major two that and EsoGuard unmet including with that insurers, testing medical the utility Board prevent We'll pre-cancer. esophageal plan population, studies notably major with for who We
is discussed the testing. in audits as establishing undergo needed. Lucid regarding implementing commitment ensure to for indicating against criteria Another They We the that through for help procedure testing sharing as for by centers collaboratively had EsoCheck risk evidence payers on test guidelines. with topic medical directors based testing a control arrangements working to mechanisms, important practice performed billed EsoGuard serve check indicator indicated and important our consistent an that with and potential will our strict who proposed testing, to EsoGuard
Board we a an begin to have set various sufficient am discussions become test in to advisory specific second additional our to in will scheduled a we We network on a approach. to direct forward looking payer, next meeting have new points. get I of a contractual on region their Medical radar, provider more often specific with Directors of and validation month submitted Once their
of European developing we're terms CE secure market Europe, a that certification now proceeding with mark strategy. we've In
consulting who us in in esophageal engaged to with strategy are opinion existing with secure based to leveraging disease help major firm We country-by-country are our relations participating Geneva and strong a Europe, trials. key leaders a clinical in execute reimbursement develop European
on me our commercialization EsoGuard with with move starting engagement Let now GIS. to
commercialization physicians. efforts are DCI EsoGuard on initial focused Our
We of that the to the embraced the enhance have they funnel EsoGuard that are notion expanding potential their gratified has patients. practice pre-cancer generally esophageal by
the well concepts. honed several is now to includes messaging Our and important GIS
few existing First, GI, their to endoscopy that less Cologuard, see EsoGuard undergo add cannibalize risk patients much endoscopy. unlike with does per seek or not an ever so compete business. Since
believe we EsoGuard expand pre-cancer dramatically practice for the widespread will funnel treatment. their diagnosis, definitive of patients and esophageal that monitoring testing in Second,
are esophageal who them in undergoing EsoGuard are and network, fourth to patients them patients candidates Third, will cancer educate the since GERD collaboratively work testing. for referring pre-cancer already testing, we there on And physician their that relationship many colonoscopy. their engage between practice, with EsoGuard including
a well well-received I as working and opening meeting boosted at Popper have Poppers our my with So in well-received David reported a past NYU. been May, and positively initial have from largest in by on world this Dr. these his EsoGuard. busiest GI the boosted EsoCheck - noted efforts has Dr. physician, GI the by remarks, experience are presentation
primary care role of the not move centers. Let's and recent our our Lucid physicians to on to of expansion include EsoGuard commercialization test
ever GERD physician. - nearly exclusively previously I portion small see them cared all small only patients by noted for GI very physicians primary and as care of a a a So
In with a patients has to positive esophageal lead early in extensive PCPs be believe for sales not in guidelines screen PCPs that dozens engagement very with on the with adverse centers. the screening cancer. can will early office-based availability experience widespread cancer simple to area GERD the fact, That's educated and pre yielded are pre-cancer. a patients risk rep procedure that His past few deaths month in referrals the prevent Phoenix new screening of PCPs of has receptive dedicated results, tests clinical to non-endoscopic Phoenix we relationship, He esophageal understand at that's cancer test withstanding, once such to GERD to them meeting they of area hired weeks. in we the scheduled driving one's PCP. This marketing to diagnostic coming for already
leased whose Phoenix medical staffed Lucid trainers and Tempe Lucid. in assistants announced operated by Scottsdale office by centers a EsoCheck practitioner Glendale, located this So in we Arizona in employed and test launch week, suites and in a medical are
office practitioner the assistant cover by these personnel XX attractive. be modest The per to leases that very procedures medical analysis nurse is center medical perform centers number to than a to clinician up necessary per estimate week. We day. per less able EsoCheck a tests of the economics and of that Our will supported be should indicates two costs procedures per single
states hope launch to remaining with then City Lake test program the once partnership in an in We to Salt acceptable, the becomes of and We should Las reimbursement most centers consumer eventually Lucid self-referrals the year EsoGuard's practitioners hope EsoGuard which marginal. next Phoenix practice physician threshold three independent without Vegas, likely will Arizona, nurse payer strictly announced US Assuming centers reached is to from volume program, also nationwide. more expand accommodate support program and become phase test to our provider Upscript that telemedicine operated with pilot allowed supervision Western steadily least Health, Denver. cities to in marketing. this direct at fully states the telemedicine into economics contiguous then These recently
expanded telemedicine and which In and development past full time engaged We over and the have to at level, the support launch team are with put markets Lucid level. order platform, be in to increasingly commercialization sales first fully quarter branded now expanded fall. recent should this senior weeks, complete leadership the and the marketing the our to significantly of to manager sales development efforts, the Upscript representative and we at ready
as previously over coming the to continue we to to team expect quarters. noted So make I substantial additions the
This program on update clinical the Finally, to let research me commercial our efficacy close efforts. clinical ongoing Lucid development our with our reimbursement a support brief evidence expand out and of regulatory program. to and seeks products
We're to GERD support non and use with with of COVID PMA European Despite years FDA patients In new management as in our XXX with esophageal These of patients patients will training preservative. In-Vitro sites XXX bail order enroll enhance still will BE-X and and Barrett's submission diagnosis more of the process we they particularly begun risk bringing introduce FDA Barrett's a of these a and and in with strong. active XXXX, with a research of approximately along in Esophagus XXXX. and study trials, enrollment over indicator dysplastic in detect April factor XX five diagnostic targeting sites to support upcoming which enrollment launched screening clinical to two non-dysplastic a clinical are Netherlands. EsoGuard completion XX of of to sites other which been international Europe, launched multicenter EsoCheck and the in control data enrolling - actively early have beginning Esophagus. the controls. dysplastic, GERD ESOGUARD our approval cancer, or U.S. since to we U.S. one previous study has in ESOGUARD are Spain decent since and the system. the age have enrollment The the end XX Europe case numbers studies to normal active We in by BE-X many XXX an PMA reboot as trials enroll in-house, the clinical infrastructure or
for I'll some those our to close provide much now with context Finally, who brief don't on time updates learning of I have background products. about or other are you PAVmed. just
I'd SEC you for filings to with So questions. as our additional refer to always, and website information us encourage any or contact
training model invasive the CarpX, enhanced a experience a momentum specifically KLOs utilizing reboot our chain National and contracted marketing working. surgery the limited not has scheduled first and challenges gotten recruitment he surgeon cadaver and our start to Medical, treat a hired the to Kevin faced Carpal build adopters and hand decided remain schedule release broaden has and extended CarpX to specifically the number the the early National build a time successfully Manager role that of frank expand look simply and team more an syndrome. the case deliberate a Manager, the training important who repeated focused hand running the steps and Carpal searching orthopedic efforts optimizing and Roberts sales, drive have device December. clients commercial cadaver and surgery beginning in We successful of early deeper invasive of and full an of building we a minimally Tunnel CarpX advisors COVID Tunnel minimally our that to and a more full early supply we this sales in CarpX commercial in issues in including of Sales a brings team them momentum of before work the quarter hands with steady fully over experience decade U.S. Kevin plan, our a end with successful said adopter started as on to was ground learned launch. to be committed efforts CarpX dividends. commercialization We first in drive commercialization of release. in large half space, Let's He by initial serve of with I'll to in and brings surgeons we and our as played case past year following recruited distributors. We completed the Kevin cases. Trice in including But CarpX volume His the and year. hit has Sales hopeful safety second early Tunnel pay quite contacts June. at towards access state that for to would is and procedural longtime to the I sessions year been in It commercialization and was cases. device. frustrating related and Carpal launch Trice
frustrating As of future including what as generations remained very which the the a technology product, things of I is still about have groundbreaking been is R&D on I've exciting underway. upbeat believe future work
wireless are healthcare includes and here optimize Next, Veris moving that more The also physicians And well. combined designed which well. do this should we to front, really the excited side some first with communication, a on with the through sensors technology device start prospects with going oncologist acquisition of about this fall. Health. both intelligent Things core provides and work patients are new going software initial an is be the and Oncodisc for digital The the rapidly tool effective implantable and hardware a testing ever position off to port remote design great with the monitoring vascular I than is technology. data we and forward to access analytics. cost platform, outcomes and design inherited delivery improve in the biologic software am animal care Things remote
software are applications. to highly both digital build the We experienced Smartphone and developers with based engaging health cloud
of NextFlo, has here collaboration. is the are healthcare Microsoft's us. team Tim to on Things been forward noted, continuing And an I news discussions As good. On very we important previously Baxter with resource potential for to looking and Internet our
set this fall this commercial fall. validation to We and our groundbreaking going in for received the clearance be positioned in to QX. in wrap building product QX up IV XXX(k) infrastructure of expect the NextFlo well verification and early We're FDA hopefully to testing file and should start our submission
the albeit advance to Our at engagement with technology. while slow application in this disposable large be strategic pace, infusion interested continues continue we pump a
to we the NextFlo set So it, sell This sets. not the commercialize consummated. past were portfolio and also an along IV company the in we're broader larger well the space by with on is deal a IV quarter positioned if strategic market leader including solicited even
our As ready forward hope Columbia, America our where planned we'll underway updates to outbreak on human severe Things appear look and port intraosseous this takes getting grinding it The to summer, as is to early America. South be IO study access of vascular I back this when track device. finalize approval us. getting and engagement implantable, process Two seeing to in and soon. South halt came patients just was commence a on the a result a COVID begin FDA across to enrolling long
in have On FDA a submission a support to package submitted U.S. pre de month trial the this U.S. IDE and novo front, to meeting finalize our we've fall. expect last application
our hope the catheters highlights brief and thermal progressing and from despite few year in data submit study collaboration continue second we pediatric DisappEAR and this molding on a tubes advance be to esophageal restorable thermal the forward. console to our process. very and our partner ablation position XXX(k) our Work of look device Finally XXXX. our infusion for to earlier close We ablation with design portfolio. in animal development manufacturing a continue Canon is the EsoCure from USA, products to innovations challenges well, emerging ear promising, histopathology in with research early some progress clearance in
is first volunteers non-invasive glucose be to model technology before Our XXXX. our I Work monitoring the FDA the on end human prototype to data going year. any ready target for milestone half date the and for have is expect of don't now technology. testing our proprietary the on animal report generation submission for diabetic a well and we new second or XXX(k) Solys of our
you your the So thank for with can And all operator, to questions. that now open attention. call we
